TORONTO, June 5 /CNW/ - Medical device manufacturers are seeking
alternatives to contaminated heparin coatings used to prevent thrombus in
medical devices. Recent studies performed on catheters treated with Interface
Biologics's Endexo(TM) additive showed a 98% reduction in thrombus
accumulation versus a control in blood loop studies.
"The difference between the Endexo(TM) additive and the control was
significant in an in-vitro flow model using bovine blood" stated Sivaprasad
Sukavaneshvar, Ph.D., Vice President of the Medical Device Evaluation Center
(MDEC) in Salt Lake City, Utah.
In Vivo sheep studies performed at MDEC tested for catheter patency
between a control and an Endexo(TM) treated catheter. Blood draws were
performed daily and over a 30 day period the Endexo additive yielded a 20%
reduction in occlusive days under aspiration, and a 50% reduction in occlusive
days under infusion versus the control.
"Both the in vitro and in vivo results show that Endexo(TM) additives
perform to the standard set by Heparin coated devices, and will provide better
patient outcomes in light of the recent adverse events and recalls. In
addition, our pre-extrusion additive yields a simple and more cost effective
manufacturing process. This provides a "win win" for medical device
manufacturers who are turning away from Heparin coated devices." said Richard
Sullivan, President and CEO of Interface Biologics Inc.
More information about recent Endexo studies is available at
About Interface Biologics Inc.: Interface Biologics is a biomaterials
company focused on producing the next generation of therapeutic medical
devices. Its additive technologies migrate to the top 10 nanometers of the
surface and are capable of influencing the surrounding biology without
affecting the mechanical properties of the device. The company is focused on
reducing thrombus and infection, two long standing clinical unmet needs.
For further information:
For further information: visit www.interfacebiologics.com or contact
Mark Steedman, (416) 673-8158